Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.82 |
| ▸ | ERBB4 | Q15303 | 7/20 | 0.82 |
| ▸ | JAK3 | P52333 | 2/20 | 0.82 |
| ▸ | GAK | O14976 | 1/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.82 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.82 |
| ▸ | LCK | P06239 | 1/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.82 |
| ▸ | SRC | P12931 | 1/20 | 0.82 |
| ▸ | DRD2 | P14416 | 1/20 | 0.82 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.82 |
| ▸ | MC3R | P41968 | 1/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.82 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.82 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994892 | 1.00 | EGFR (0.82) | EGFRERBB2ERBB4JAK3GAK | |
| Dacomitinib Anhydrous SCHEMBL29396914 | 0.90 | EGFR (1.00) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL30115337 | 0.90 | EGFR (1.00) | EGFRERBB2ERBB4JAK3GAK | |
| Dacomitinib Anhydrous SCHEMBL25637 | 0.90 | EGFR (1.00) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL25098 | 0.90 | EGFR (1.00) | EGFRERBB2ERBB4JAK3GAK | |
| Dacomitinib Anhydrous SCHEMBL29354322 | 0.90 | EGFR (1.00) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL33136 | 0.90 | EGFR (1.00) | EGFRERBB2ERBB4JAK3GAK | |
| Dacomitinib Anhydrous SCHEMBL33147 | 0.90 | EGFR (1.00) | EGFRERBB2ERBB4JAK3GAK | |
| Dacomitinib Anhydrous SCHEMBL29377735 | 0.90 | EGFR (1.00) | EGFRERBB2ERBB4JAK3GAK | |
| Dacomitinib Anhydrous SCHEMBL22498351 | 0.89 | EGFR (1.00) | EGFRERBB2ERBB4JAK3GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2712320-B1 | METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2019-10-02 | — | — | EP | disclosed |
| US-20160101175-A1 | METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2016-04-14 | — | — | US | disclosed |
| US-20140341926-A1 | METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8828391-B2 | Method for EGFR directed combination treatment of non-small cell lung cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-8623883-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130274275-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC | 2013-10-17 | — | — | US | disclosed |
| US-8466165-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120294867-A1 | METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20100190977-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| EP-1746999-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | Warner-Lambert Company LLC (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005107758-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101175-A1 | METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ERBB4 4/4885 |
| US-20140341926-A1 | METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ERBB4 4/4885 |
| US-20100190977-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | HRH4, HRH3, HRH2 | EGFR 1504/4885ERBB2 1415/4885ERBB4 1648/4885 |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | JAK1, JAK2, EDNRA | EGFR 41/4885ERBB2 8/4885ERBB4 38/4885 |
| US-20120294867-A1 | METHOD FOR EGFR DIRECTED COMBINATION TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ERBB4 4/4885 |
| US-20130274275-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | HRH4, HRH3, HRH2 | EGFR 1504/4885ERBB2 1415/4885ERBB4 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.